Results 231 to 240 of about 3,099,670 (313)

A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand

, 2018
Lijoy Varghese, Louise Talbot, Andrea Govender, Xuhao Zhang, Bruce A. Mungall   +4 more
openalex   +1 more source

Financial Distress and Its Determinants in Rheumatoid Arthritis

Arthritis Care &Research, EarlyView.
Objective To quantify the degree of financial distress and identify its determinants in adults with rheumatoid arthritis (RA) given the frequent prolonged use of expensive disease‐modifying therapies. Methods We identified adults enrolled in the FORWARD databank with either RA or noninflammatory musculoskeletal disease (NIMSKD) completing the ...
Amber Brown Keebler, Yunju Im, Sofia Pedro, Ted R. Mikuls, Edward S. Peters, Kaleb Michaud   +5 more
wiley   +1 more source

Evaluating the long-term cost-effectiveness of the COBRA-BPS programme in Pakistan. [PDF]

BMJ Public Health
Chivardi C, Samad Z, Chen T, Walker SM.
europepmc   +1 more source

A Qualitative Analysis of Patient Perspectives and Preferences in Lupus Management to Guide Lupus Guidelines Development

Arthritis Care &Research, EarlyView.
Objective A patient‐centered approach for chronic disease management, including systemic lupus erythematosus (SLE), aligns treatment with patients’ values and preferences, leading to improved outcomes. This paper summarizes how patient experiences, perspectives, and priorities informed the American College of Rheumatology (ACR) 2024 Lupus Nephritis (LN)
Shivani Garg, Izzy Hartel, Lisa R. Sammaritano, Anca Askanase, Bonnie L. Bermas, Maria Dall'Era, Alí Duarte‐García, Victoria P. Werth, Brad Rovin, Reem A. Mustafa, Amy S. Turner, Bené Williams, Brian L. Ung, Hiya Bhavsar, Monique C. Gore‐Massy, Nahirannette Pulido, Natacha Guerrero, Natalie M. Smith, Wambui Machua, Linda T. Hiraki, Mary Beth Son   +20 more
wiley   +1 more source

The cost-effectiveness of penicillin allergy assessment pathway (PAAP): a decision analysis. [PDF]

BMJ Open
Yang M, Bestwick R, Howdon D, Ahmed S, Powell N, Armitage KF, Fielding J, Porter CE, Savic S, West RM, Howard P, Galal U, Pavitt S, Sandoe JA, Mujica-Mota RE.   +14 more
europepmc   +1 more source

Sex differences in medication discontinuation in axial spondyloarthritis.

Arthritis Care &Research, Accepted Article.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or Janus kinase inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source

Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease

Arthritis Care &Research, Accepted Article.
Objectives Sjögren's disease is an autoimmune disorder that can impact multiple organ systems, including the peripheral nervous system (PNS). PNS manifestations, which can exist concurrently, include mononeuropathies, polyneuropathies, and autonomic nervous system neuropathies. To help patients and providers in the decision‐making process, we developed
Anahita Deboo, Robert Fox, Katherine M. Hammitt, Julie Frantsve‐Hawley, Matthew C. Baker, Stamatina Danielides, Eduardo De Sousa, Brent P. Goodman, Jennifer K. King, Steven Mandel, Ghaith Noaiseh, Pantelis P. Pavlakis, George Sarka, R. Hal Scofield, Arun Varadhachary, Daniel J. Wallace, Matt Makara, Nancy Carteron, Steven Carsons, In collaboration with the Consensus Expert Panel (CEP) members   +19 more
wiley   +1 more source

Cost-effectiveness of emicizumab for the treatment of hemophilia A: a systematic review. [PDF]

Front Public Health
Chen M, Lin Y, He G, Huang L, Han J, Ni J.   +5 more
europepmc   +1 more source

Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States

, 2015
Thomas E. Delea, Jordan Amdahl, Jose Diaz, Hamid Reza Nakhai-Pour, Michelle D. Hackshaw   +4 more
openalex   +2 more sources

Evidence and Cost Effectiveness Requirements for Recommending New Biomarkers. [PDF]

, 2015
Collinson, P
core   +1 more source